Richard Hoglund

Head of Pharmacometrics

Clinical Pharmacology

Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.

More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.

Recent publications

Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa
Journal article

Fanello C. et al, (2021), Antimicrobial Agents and Chemotherapy, 65
Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
Journal article

Wattanakul T. et al, (2021), Antimicrobial Agents and Chemotherapy, 65
Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
Journal article

Panjasawatwong N. et al, (2020), Antimicrobial Agents and Chemotherapy, 65, e00487 - 20
Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence".
Journal article

Ding J. et al, (2020), Clinical pharmacology and therapeutics
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
Journal article

White NJ. et al, (2020), PLOS Medicine, 17, e1003252 - e1003252

More publications